MEET OUR MANAGEMENT TEAM
Our team of visionaries combines the boldness of big pharma with the agility of startups to drive a new era of dermatology and help people achieve healthier skin.
Fred Hockenjos Jr.
Vice President, Sales
Fred Hockenjos brings more than 20 years of experience to his role as the Vice President of Sales at Dermavant. After working his way up from multiple specialty sales positions at Pfizer to director roles at Medicis and Valeant Pharmaceuticals, he became Vice President of Sales and Commercial Strategy at Galderma before leading our team. Mr. Hockenjos graduated with a BS in finance from Brigham Young University.
Jake DeBoever
Vice President, Chief Compliance Officer
Since 2021, Jake DeBoever has brought significant compliance and corporate experience to the Dermavant team. His previous roles as Vice President and Chief Compliance Officer at Galderma and Vice President of Compliance and Ethics at McKesson helped build his extensive knowledge of healthcare, prescription drugs, medical devices, drug distribution, litigation, antitrust, and more. He graduated with a bachelor’s in public policy from Hamilton College and a JD from Washington University School of Law in St. Louis.
Elaine Clark
Vice President, Regulatory Affairs
Elaine Clark is an accomplished development professional with over 20 years of industry experience, ranging from startup biotech to CRO and global commercial organizations. As the Vice President of Global Regulatory Affairs at PRA Health, Ms. Clark was responsible for regulatory CMC, labeling and emerging market regulatory activities for a portfolio of Takeda marketed products, and oversaw all regulatory activities within the prescription business unit as the Head of Global Regulatory Affairs at Galderma. During her time as the Head of Regulatory Affairs for Lexicon Pharmaceuticals, she oversaw successful IND/CTA filings for seven first-in-class new molecular entities to enable first-in-human trials.
Chad Berryhill
Vice President, Information Technology
Chad Berryhill brings more than 20 years of experience to his position as Dermavant’s Vice President of Information Technology. He held the position of Director of IT across multiple companies – including Medicis, Dogeared, and Traffic Management, Inc. – before joining Dermavant in 2018. Mr. Berryhill graduated with a bachelor’s in business management from Western Governors University.
Anna Tallman, PharmD
Vice President, Medical Affairs
Anna Tallman combines 20 years of medical affairs leadership with in-depth clinical experience in therapeutic areas, including dermatology, infectious disease, central nervous system, and pain. Dr. Tallman previously served as Global Therapeutic Area Team Leader, Dermatology, and Senior Medical Director, Dermatology, at Pfizer, and was instrumental in successfully launching products at Optimer Pharmaceuticals, Strativa Pharmaceuticals, and Elan Pharmaceuticals. Dr. Tallman earned her Doctor of Pharmacy degree from the University of Michigan.
Kenneth Peist
Vice President, Intellectual Property
Kenneth Peist specializes in IP due diligence, maximizing patent and regulatory exclusivity for pharmaceutical products, patent portfolio management and licensing, and M&A support and has served as Dermavant’s Vice President of Intellectual Property (IP) since October 2018. His prior ventures include Senior Partner, Legal, at Roivant Sciences and a variety of legal positions at Amicus Therapeutics, Bristol Myers Squibb, Vitae Pharmaceuticals, and ExxonMobil, culminating in more than 20 years of experience. Dr. Peist received his JD from Seton Hall University School of Law and a BS from Old Dominion University.
Kristopher Garcia
Vice President, Corporate Controller
Kristopher Garcia brings over 20 years of combined experience in finance leadership, audit, and advisory roles. He previously served as Vice President of Finance at Evolus, Inc. and as Head of Finance and Vice President, Controller, at ALPHAEON, and he has over a decade of audit and advisory experience at PricewaterhouseCoopers. Mr. Garcia graduated with a Bachelor of Arts degree from Concordia University.
Diana Villalobos
Vice President, Clinical Operations
After 20 years of holding key roles across drug development – including international experiences, leading and managing clinical teams, and serving as Vice President of Clinical Operations at Veristat – Diana Villalobos was well prepared to join Dermavant. Ms. Villalobos’ depth of experience in leading global teams and managing large-scale phase 3 programs is invaluable to Dermavant’s clinical team.
Steve Piscitelli, PharmD
Vice President, Head of Clinical Development
Steve Piscitelli has over 25 years of drug development experience and clinical pharmacology expertise across government, biotech, and large pharma areas. Prior to joining the pharmaceutical industry, Dr. Piscitelli served as the coordinator of the Clinical Pharmacokinetics Laboratory at the National Institutes of Health and completed a secondment at the Food and Drug Administration as a clinical pharmacology reviewer. He has published over 125 papers in the medical literature, co-edited a drug interactions textbook, and is a co-inventor on a number of patents. He was responsible for clinical pharmacology strategy across several therapeutic areas as Vice President of Clinical Pharmacology at Roivant Sciences and contributed to worldwide approval of multiple drugs during his time at GlaxoSmithKline and Tibotec-Virco. He received his PharmD degree from SUNY Buffalo and completed a residency and fellowship at the University of Illinois at Chicago.
Darren Lenczycki
Vice President, Business Operations & Intelligence
Joining Dermavant in 2020, Darren Lenczycki’s 15+ years of business expertise ranges from startups to commercial execution. His prior roles include Senior Product Manager at Taro Pharmaceuticals and Director of Strategic Channels at Galderma, where he exercised and grew his ability to lead high-performing teams and spearhead cross-functional and customer-focused initiatives. Mr. Lenczycki graduated with a BA in economics from Tulane University and an MBA in finance and accounting from Saint Joseph’s University.
John Darden
Vice President, Marketing
John Darden has over 15 years experience in the biopharmaceutical industry. Prior to joining Dermavant, Mr. Darden served various roles at Amgen, most recently as the Executive Director, Marketing and U.S. brand lead for Otezla. He led several successful launches in the dermatology and immunology space and has deep experience in market access where he led payer coverage strategy. Mr. Darden received a BS from Duke University and a Masters in Business from University of Virginia.
Carey Herbert
Vice President, Legal
With more than 20 years of experience, Carey Herbert brings prominent industry experience to her role. Her series of accomplishments includes Assistant General Counsel across several companies and Chair of Corporate Transactions at Rose Law Group pc before joining Dermavant in 2018. Her academic accolades include a Master of Business Administration from the University of Alberta, a Ph.D. in philosophy from the University of Arizona, and a JD from the University of Arizona’s James E. Rogers College of Law.
John Cheslock
Vice President, Access & Pricing
John Cheslock has spent over 25 years in the industry and brings a plethora of expertise to his role as Dermavant’s Vice President of Access and Pricing. Before joining the team in 2021, he was the Director of Contracts and Pricing across several companies – including Archimedes Pharma, Orexo US Inc., and Galderma – where he demonstrated his versatility and industry knowledge. He graduated from Penn State University with a bachelor’s in health planning administration and an MBA.
Experience what sets our culture apart